Company: EDSA
Filing Date: 2025-09-09
Form Type: 424B5
Source: 0001171843-25-005799
Chunk: 1

Company: Edesa Biotech, Inc.
Filing Date: 2025-09-09
Form: 424B5
Chunk 1
---
 Sales Agreement, the Sales Agent is not required to sell any specific
number or dollar amounts of securities but will act as a sales agent using commercially reasonable efforts consistent with its normal
trading and sales practices, on mutually agreed terms between the Sales Agent and us. There is no arrangement for funds to be received
in any escrow, trust or similar arrangement.

The Sales Agent will be entitled to compensation under the terms of the
Sales Agreement at a commission rate of 3.0% of the gross sales price per share sold. In connection with the sale of our common shares
on our behalf, the Sales Agent will be deemed to be an “underwriter” within the meaning of the Securities Act and the compensation
of the Sales Agent will be deemed to be underwriting commissions or discounts. We have also agreed to provide indemnification and contribution
to the Sales Agent with respect to certain liabilities, including liabilities under the Securities Act. See the section titled “Plan of Distribution” on page S-21 of this prospectus supplement. This offering pursuant to this prospectus supplement and the accompanying
prospectus will terminate upon the earlier of (a) the sale of our common shares pursuant to this prospectus supplement and the accompanying
prospectus having an aggregate sales price of $4,006,544, or (b) the termination by us or the Sales Agent of the Sales Agreement pursuant
to its terms.

As of the date of this prospectus supplement, the aggregate market value
of our outstanding common shares held by non-affiliates, or the public float, was $14,531,034.76, which was calculated based on 5,743,492
outstanding common shares held by non-affiliates at a price of $2.53 per share, the closing price of our common shares on September 5,
2025, as reported on Nasdaq. Pursuant to General Instruction I.B.6 of Form S-3, in no event will we sell shares pursuant to this prospectus
with a value of more than one-third of the aggregate market value of our common shares held by non-affiliates in any 12 calendar month
period, so long as the aggregate market value of our common shares held by non-affiliates is less than $75,000,000. During the 12 calendar
months prior to, and including, the date of this prospectus supplement, we have sold $837,134 of our securities pursuant to General Instruction
I.B.6 of Form